The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
May 22, 2017
View Complete Issue         Table of Contents 2019 
Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
May 22, 2017 (Issue: 1521)
The FDA has approved a subcutaneously administered 20% solution of human immune globulin (Cuvitru – Shire) for replacement therapy in patients ≥2 years old with a primary humoral immunodeficiency. Hizentra (CSL Behring), another...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Another Subcutaneous Immune Globulin (Cuvitru) for Primary Immunodeficiency (online only)
Article code: 1521e
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.